Recent advances in molecular genetics of breast cancer

Journal of Molecular Medicine

Volumn 79, Issue 10, 2001, Pages 566-573

  Pavelić, Krešimir ^a   Gall Trošelj, Koraljka ^a  

^a RUDER BO KOVI INSTITUTE   (Croatia)

Author keywords

"Intelligent" therapy; BRCA1; Breast cancer; Molecular genetics; Signaling

Indexed keywords

CATENIN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SOMATOMEDIN BINDING PROTEIN 4; STRESS ACTIVATED PROTEIN KINASE;

APOPTOSIS; BREAST CARCINOMA; CANCER CLASSIFICATION; CELL CYCLE; CHROMATIN STRUCTURE; CHROMOSOME DAMAGE; DNA DAMAGE; DNA MICROARRAY; DNA SEQUENCE; ENZYME ACTIVATION; GENE ACTIVITY; GENE EXPRESSION; GENE FUNCTION; GENE INDUCTION; GENE TARGETING; HUMAN; MOLECULAR GENETICS; REVIEW; SIGNAL TRANSDUCTION; SOMATIC CELL GENETICS; TRANSCRIPTION REGULATION; TUMOR GROWTH;

BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; FEMALE; GENETIC SCREENING; HUMANS; MUTATION;

EID: 0034796054     PISSN: 09462716     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001090100256     Document Type: Review

References (58)

1. Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland
2. DNA hypermethylation in tumorigenesis - Epigenetics joins genetics
3. Molecular mechanisms of anticancer activity of natural dietetic products
4. Nutrition, genetics, and risks of cancer
5. The genetics of breast cancer susceptibility
6. Developmental sudies of BRCA1 and BRCA2 knock-out mice
7. Clinico-pathological characteristics of BRCA1-and BRCA2-related breast cancer
8. Association of BRCA1 with Rad 51 in mitotic and meiotic cells
9. BRCA1 effects on the cell cycle and the DNA damage response are linked to altered gene expression
10. WAF 1, a potential mediator of p53 tumor suppression
11. WAF1/CIP1
12. BRCA 1 physically associates with p53 and stimulates its transcriptional activity
13. BRCA 1 is a component of the RNA polymerase II holoenzyme
14. Nuclear localization and cell cycle specific expression of CtIP, a protein that associates with BRCA1 tumor suppressor
15. BRCA-1 binds c-myc and inhibits its transcriptional and transforming activity in cells
16. Induction of GADD45 and JNK/SAPK-dependent apoptosis following inducible expression of BRCA 1
17. BRCA 1 is associated with a human SWI/SNF-related complex: Linking chromatin remodeling to breast cancer
18. The Swi/Snf family - Nucleosome - Remodeling complexes and transcriptional control
19. Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer
20. hCds1-mediated phosphorylation of BRCA1 regulates the DNA damage response
21. Human genome studies expected to revolutionize cancer classification
22. Molecular portraits of human breast tumours
23. Genetic changes in breast cancer detected by comparative genomic hybridisation
24. Protein function in the post-genomic era
25. Proteomics to study genes and genomes
26. Genetic testing - Present and future
27. Inherited cancer syndromes in gynaecology: What the practitioner needs to know!
28. Mutations of the BRCA1 and BRCA2 genes and the possibilities for predictive testing
29. BRCA 1 and BRCA 2 gene mutations and risk of breast cancer public health perspectives
30. Cell signalling and cancer treatment
31. Signal transduction takes centre stage
32. The discovery and validation of new drug targets in cancer
33. Polo-like kinase 1, a new target for antisense tumor therapy
34. Malignant transformation of mammalian cells initiated by constitutive expression of the polo-like kinase
35. Antibody microinjection reveals an essential role for human polo-like kinase 1 (Plk 1) in the functional maturation of mitotic centrosomes
36. A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers
37. Frequent amplification of chromosomal region 20q12-q13 in ovarian cancer
38. Tumour amplified kinase Stk15/BTAK induces centrosome amplification, aneuploidy and transformation
39. Markers of tumor angiogenesis and proteolysis independently define high- and low-risk subsets of node-negative breast cancer patients
40. Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction
41. Direct regulation of the Akt proto-oncogene product by phosphatidyl-inositol-3:4-bisphosphate
42. Dual role of phosphatidylinositol-3:4,5-trisphosphate in the activation of protein kinase B
43. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas
44. Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA
45. Heregulin induces phosphorylation of BRCA 1 through phosphatidylinositol 3-kinase/Akt in breast cancer cells
46. Apoptosis of human erythroid colony-forming cells is decreased by stem cell factor and insulin-like growth factor I as well as erythropoietin
47. c-Myc induced apoptosis in fibroblasts is inhibited by specific cytokines
48. Insulin-like growth factor (IGF-1) and the IGF-I receptor prevent the etoposide-induced apoptosis
49. Suppression of interleukin-1beta-converting enzyme-mediated cell death by insulin-like growth factor
50. Antiapoptotic signaling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt
51. Insulin-like growth factor-I receptor. Structure, ligand binding mechanism and signal transduction
52. Overexpression of the human insulin like growth factor I receptor promotes ligand-dependent neoplastic transformation
53. Dominant negative inhibition of tumorigenesis in vivo by human insulin-like growth factor I receptor mutant
54. The expression and role of insulin-like growth factor II in malignant hemangiopericytomas
55. Insulin-like growth factor family in malignant haemangiopericytomas: The expression and role of insulin-like growth factor I receptor
56. Agents that target telomerase and telomeres
57. Extension of lifespan by introduction of telomerase into normal human cells
58. Correlation between tumor vascularity, vascular endothelial growth factor production by tumor cells, serum vascular endothelial growth factor levels, and serum angiogenic activity in patients with breast carcinoma